Prothena Announces Proposed Offering of Ordinary Shares
March 23, 2021 16:29 ET
|
Prothena Corporation plc
DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
March 08, 2021 16:05 ET
|
Prothena Corporation plc
Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s diseaseNew analyses of prasinezumab continue to support potential disease modifying...
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
February 24, 2021 16:05 ET
|
Prothena Corporation plc
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital...
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
February 11, 2021 08:00 ET
|
Prothena Corporation plc
Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020; quarter-end cash and restricted cash position of $298.1 million...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2021 16:05 ET
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
February 04, 2021 16:05 ET
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational...
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
February 01, 2021 16:15 ET
|
Prothena Corporation plc
Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months)SPA agreement...
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
December 09, 2020 08:00 ET
|
Prothena Corporation plc
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 pointsImprovement in neuropathy for...
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2020 16:05 ET
|
Prothena Corporation plc
DUBLIN, Ireland, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of...
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
November 04, 2020 16:05 ET
|
Prothena Corporation plc
Net cash used in operating and investing activities was $19.5 million in the third quarter and $61.4 million for the first nine months of 2020; quarter-end cash and restricted cash position of $317.2...